When to wait for more evidence? real options analysis in proton therapy

Oncologist

Volumn 16, Issue 12, 2011, Pages 1752-1761

  Grutters, JANNEKE P C ^a   Abrams, Keith R ^b   de Ruysscher, Dirk ^c   Pijls Johannesma, Madelon ^c   Peters, HANS J M ^a   Beutner, Eric ^a   Lambin, Philippe ^c   Joore, Manuela A ^a,d  

^a MAASTRICHT UNIVERSITY   (Netherlands)

^b UNIVERSITY OF LEICESTER   (United Kingdom)

^c MAASTRICHT UNIVERSITY   (Netherlands)

^d MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Decision making; Lung neoplasms; Protons; Radiotherapy; Technology assessment; Uncertainty

Indexed keywords

ANALYSIS; ARTICLE; COST EFFECTIVENESS ANALYSIS; DECISION MAKING; HEALTH CARE COST; HUMAN; INOPERABLE CANCER; LUNG NON SMALL CELL CANCER; PRIORITY JOURNAL; PROTON THERAPY; REAL OPTIONS ANALYSIS; STEREOTACTIC BODY RADIATION THERAPY; TREATMENT OUTCOME; UNCERTAINTY;

CARCINOMA, NON-SMALL-CELL LUNG; COST-BENEFIT ANALYSIS; DECISION MAKING; DIFFUSION OF INNOVATION; HUMANS; LUNG NEOPLASMS; NETHERLANDS; PROTONS; RADIOSURGERY;

EID: 84855165341     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2011-0029     Document Type: Article

References (54)

1. Elkin EB, Bach PB. Cancer's next frontier: addressing high and increasing costs. JAMA 2010; 303:1086-1087.
2. Meropol NJ, Schrag D, Smith TJ et al. American Society of Clinical Oncology guidance statement: the cost of cancer care. J Clin Oncol 2009;27: 3868-3874.
3. Truffer CJ, Keehan S, Smith S et al. Health spending projections through 2019: the recession's impact continues. Health Aff (Millwood) 2010;29: 522-529.
4. Zietman A, Goitein M, Tepper JE. Technology evolution: is it survival of the fittest? J Clin Oncol 2010;28:4275-4279.
5. Drummond MF, Sculpher MJ, Torrance GW et al. Methods for the Economic Evaluation of Health Care Programmes, 3rd ed. New York: Oxford University Press, 2005.
6. Mason A, Drummond M, Ramsey S et al. Comparison of anticancer drug coverage decisions in the United States and United Kingdom: does the evidence support the rhetoric? J Clin Oncol 2010;28: 3234-3238.
7. Mullins CD, Montgomery R, Tunis S. Uncertainty in assessing value of oncology treatments. The Oncologist 2010;15 Suppl 1:58-64.
8. Schulz-Ertner D, Tsujii H. Particle radiation therapy using proton and heavier ion beams. J Clin Oncol 2007;25:953-964.
9. Goozner M. The proton beam debate: are facilities outstripping the evidence? J Natl Cancer Inst 2010;102:450-453.
10. Brada M, Pijls-Johannesma M, De Ruysscher D. Proton therapy in clinical practice: current clinical evidence. J Clin Oncol 2007;25:965-970.
11. Brada M, Pijls-Johannesma M, De Ruysscher D. Current clinical evidence for proton therapy. Cancer J 2009;15:319-324.
12. Olsen DR, Bruland OS, FrykholmGet al. Proton therapy-a systematic review of clinical effectiveness. Radiother Oncol 2007;83:123-132.
13. Peeters A, Grutters JP, Pijls-Johannesma M et al. How costly is particle therapy? Cost analysis of external beam radiotherapy with carbon-ions, protons and photons. Radiother Oncol 2010;95:45-53.
14. Grutters JP, Pijls-Johannesma M, Ruysscher DD et al. The cost-effectiveness of particle therapy in non-small cell lung cancer: exploring decision uncertainty and areas for future research. Cancer Treat Rev 2010;36:468-476.
15. Chalkidou K, Lord J, Fischer A et al. Evidence-based decision making: when should we wait for more information? Health Aff (Millwood) 2008;27:1642-1653.
16. Eckermann S, Willan AR. Expected value of information and decision making in HTA. Health Econ 2007;16:195-209.
17. Dixit AK, Pindyck RS. Investment under uncertainty. Princeton, NJ: Princeton University Press, 1994.
18. Trigeorgis. Real Options: Managerial Flexibility and Strategy in Resource Allocation. Cambridge, MA: The MIT Press, 1996.
19. Attema AE, Lugner AK, Feenstra TL. Investment in antiviral drugs: a real options approach. Health Econ 2010;19:1240-1254.
20. Claxton K, Sculpher M, Drummond M. A rational framework for decision making by the National Institute For Clinical Excellence (NICE). Lancet 2002;360:711-715.
21. Sculpher M, Claxton K. Establishing the costeffectiveness of new pharmaceuticals under conditions of uncertainty-when is there sufficient evidence? Value Health 2005;8:433-446.
22. Palmer S, Smith PC. Incorporating option values into the economic evaluation of health care technologies. J Health Econ 2000;19:755-766.
23. Willan AR, Pinto EM. The value of information and optimal clinical trial design. Stat Med 2005;24:1791-1806.
24. Briggs A, Claxton K, Sculpher M. Decision Modelling for Health Economic Evaluation. New York: Oxford University Press, 2006.
25. O'Dowd A. Government seeks suitable sites for proton beam therapy. BMJ 2009;339:b3389.
26. Health Care Insurance Board. Proton therapy (in Dutch). Diemen, the Netherlands: Health Care Insurance Board, 2009.
27. Huybrechts M, Obyn C, Gailly J et al. Hadrontherapy. Brussels: Belgian Health Care Knowlegde Centre, 2007.
28. Lodge M, Pijls-Johannesma M, Stirk L et al. A systematic literature review of the clinical and costeffectiveness of hadron therapy in cancer. Radiother Oncol 2007;83:110-122.
29. Anonymous. Introducing new treatments and technologies into the clinic. J Clin Oncol 2008;26: 2425.
30. Glimelius B, Montelius A. Proton beam therapy-do we need the randomised trials and can we do them? Radiother Oncol 2007;83:105-109.
31. Goitein M. Magical protons? Int J Radiat Oncol Biol Phys 2008;70:654-656.
32. Goitein M. Trials and tribulations in charged particle radiotherapy. Radiother Oncol 2010;95: 23-31.
33. Goitein M, Cox JD. Should randomized clinical trials be required for proton radiotherapy? J Clin Oncol 2008;26:175-176.
34. Hofmann B. Fallacies in the arguments for new technology: the case of proton therapy. J Med Ethics 2009;35:684-687.
35. Lewis BE. On equipoise and emerging technologies. J Clin Oncol 2008;26:2590; author reply 2593-2596.
36. Macbeth FR, Williams MV. Proton therapy should be tested in randomized trials. J Clin Oncol 2008;26:2590-2591; author reply 2593-2596.
37. Morgan JP. A patient's perspective on randomized clinical trials for proton radiotherapy. J Clin Oncol 2008;26:2592; author reply 2592-2593.
38. Suit H, Kooy H, Trofimov A et al. Should positive phase III clinical trial data be required before proton beam therapy is more widely adopted? No. Radiother Oncol 2008;86:148-153.
39. Tepper JE. Protons and parachutes. J Clin Oncol 2008;26:2436-2437.
40. Grutters JP, Kessels AG, Pijls-JohannesmaM et al. Comparison of the effectiveness of radiotherapy with photons, protons and carbon-ions for nonsmall cell lung cancer: a meta-analysis. Radiother Oncol 2010;95:32-40.
41. Council for Public Health and Health Care. Sensible and sustainable care (in Dutch). Zoetermeer, the Netherlands: Council for Public Health and Health Care, 2006.
42. Ades AE, Lu G, Higgins JP. The interpretation of random-effects meta-analysis in decision models. Med Decis Making 2005;25:646-654.
43. Briggs A, Ritchie K, Fenwick E et al. Access with evidence development in the UK: Past experience, current initiatives and future potential. Pharmacoeconomics 2010;28:163-170.
44. Pertile P. An extension of the real option approach to the evaluation of health care technologies: The case of positron emission tomography. Int J Health Care Finance Econ 2009;9:317-332.
45. Pertile P, Torri E, Flor L et al. The timing of adoption of positron emission tomography: a real options approach. Health Care Manag Sci 2009;12: 217-227.
46. Driffield T, Smith PC. A real options approach to watchful waiting: theory and an illustration. Med Decis Making 2007;27:178-188.
47. Carlson JJ, Garrison LP, Ramsey SD et al. The potential clinical and economic outcomes of pharmacogenomic approaches to EGFR-tyrosine kinase inhibitor therapy in non-small-cell lung cancer. Value Health 2009;12:20-27.
48. Collins R, Fenwick E, Trowman R et al. A systematic review and economic model of the clinical effectiveness and cost-effectiveness of docetaxel in combination with prednisone or prednisolone for the treatment of hormone-refractory metastatic prostate cancer. Health Technol Assess 2007;11:iii-iv, xv-xviii, 1-179.
49. Garside R, Pitt M, Somerville M et al. Surveillance of Barrett's oesophagus: Exploring the uncertainty through systematic review, expert workshop and economic modelling. Health Technol Assess 2006;10:1-142, iii-iv.
50. Hassan C, Pickhardt PJ, Di Giulio E et al. Value-of-information analysis to guide future research in the management of the colorectal malignant polyp. Dis Colon Rectum 2010;53:135-142.
51. Wild C, Langer T. Emerging health technologies: informing and supporting health policy early. Health Policy 2008;87:160-171.
52. Holm S, Takala T. High hopes and automatic escalators: a critique of some new arguments in bioethics. J Med Ethics 2007;33:1-4.
53. Dutch Cancer Registry. http://www.ikcnet.nl/index.php. Accessed 2010.
54. Health Care Insurance Board (CvZ). Guidelines for pharmaco-economic research (In Dutch). Diemen, the Netherlands: Health Care Insurance Board, 2006.